NewEdge Wealth LLC Makes New $682,000 Investment in Zimmer Biomet Holdings, Inc. $ZBH

NewEdge Wealth LLC bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 6,923 shares of the medical equipment provider’s stock, valued at approximately $682,000.

A number of other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Zimmer Biomet by 0.9% during the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock worth $2,120,751,000 after purchasing an additional 198,370 shares during the last quarter. Dodge & Cox lifted its position in shares of Zimmer Biomet by 12.9% during the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock worth $2,015,510,000 after buying an additional 2,533,009 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Zimmer Biomet by 8.7% in the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock worth $520,752,000 after buying an additional 458,903 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Zimmer Biomet by 1.4% in the second quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after acquiring an additional 69,485 shares in the last quarter. Finally, Primecap Management Co. CA increased its position in shares of Zimmer Biomet by 0.6% during the second quarter. Primecap Management Co. CA now owns 4,710,830 shares of the medical equipment provider’s stock valued at $429,675,000 after acquiring an additional 27,860 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Price Performance

ZBH opened at $99.39 on Tuesday. The firm has a 50-day moving average price of $90.78 and a 200-day moving average price of $95.89. Zimmer Biomet Holdings, Inc. has a twelve month low of $84.59 and a twelve month high of $114.44. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $19.70 billion, a price-to-earnings ratio of 28.08, a PEG ratio of 2.02 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same period last year, the firm earned $2.31 EPS. Zimmer Biomet’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s payout ratio is presently 27.12%.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. restated a “neutral” rating and issued a $100.00 price objective (down previously from $115.00) on shares of Zimmer Biomet in a research note on Thursday, November 6th. Wall Street Zen downgraded shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Citigroup restated a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. Wells Fargo & Company boosted their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 11th. Finally, Sanford C. Bernstein raised their price target on shares of Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.